| Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review A Prelaj, V Miskovic, M Zanitti, F Trovo, C Genova, G Viscardi, SE Rebuzzi, ... Annals of Oncology, 2023 | 76 | 2023 |
| Immune cell engagers in solid tumors: promises and challenges of the next generation immunotherapy G Fucà, A Spagnoletti, M Ambrosini, F De Braud, M Di Nicola ESMO open 6 (1), 100046, 2021 | 43 | 2021 |
| Cancer-related fatigue and depression: a monocentric, prospective, cross-sectional study in advanced solid tumors R Lobefaro, S Rota, L Porcu, C Brunelli, S Alfieri, E Zito, I Taglialatela, ... ESMO open 7 (2), 100457, 2022 | 20 | 2022 |
| Real-world data to build explainable trustworthy artificial intelligence models for prediction of immunotherapy efficacy in NSCLC patients A Prelaj, EG Galli, V Miskovic, M Pesenti, G Viscardi, B Pedica, L Mazzeo, ... Frontiers in Oncology 12, 1078822, 2023 | 12 | 2023 |
| 1689O Comprehensive mapping review of real-world evidence publications focusing on targeted therapies in solid tumors: A collaborative work from ESMO real-world data and … A Pellat, T Grinda, A Prelaj, P Cresta, A Valachis, I Zerdes, DM Branco, ... Annals of Oncology 34, S925, 2023 | 8 | 2023 |
| PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1< 50%: a multiomics analysis GL Russo, A Prelaj, J Dolezal, T Beninato, L Agnelli, T Triulzi, A Fabbri, ... Journal for Immunotherapy of Cancer 11 (6), 2023 | 7 | 2023 |
| Prognostic and predictive role of body mass index (BMI) in metastatic colorectal cancer (mCRC): a pooled analisys of tribe and tribe-2 studies by GONO E Dell'Aquila, D Rossini, A Galletti, M Stellato, A Boccaccino, V Conca, ... Clinical Colorectal Cancer 21 (3), 220-228, 2022 | 6 | 2022 |
| APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research A Prelaj, M Ganzinelli, L Provenzano, L Mazzeo, G Viscardi, G Metro, ... Clinical Lung Cancer 25 (2), 190-195, 2024 | 3 | 2024 |
| Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma RS Goodman, L Di Guardo, A Maurichi, B Kirwin, A Khattak, V Vanella, ... European Journal of Cancer 194, 113354, 2023 | 3 | 2023 |
| Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease A Spagnoletti, M Platania, M Brambilla, M Occhipinti, L Canziani, ... Tumori Journal 108 (6), 609-614, 2022 | 3 | 2022 |
| Bone metastases are associated with worse prognosis in patients affected by metastatic colorectal cancer treated with doublet or triplet chemotherapy plus bevacizumab: a … E Dell’Aquila, D Rossini, CAM Fulgenzi, A Passardi, E Tamburini, ... ESMO open 7 (6), 100606, 2022 | 2 | 2022 |
| Primary Tumor Resection in Synchronous Metastatic Colorectal Cancer Patients Treated with Upfront Chemotherapy plus Bevacizumab: A Pooled Analysis of TRIBE and TRIBE2 Studies V Fanotto, D Rossini, M Casagrande, F Bergamo, A Spagnoletti, D Santini, ... Cancers 15 (22), 5451, 2023 | 1 | 2023 |
| Efficacy of mRNA anti-SARS-CoV-2 vaccination and dynamics of humoral immune response in patients with solid tumors: results from the institutional registry of an Italian … G Fucà, M Lecchi, CM Ciniselli, A Ottini, A Spagnoletti, L Mazzeo, ... Therapeutic Advances in Medical Oncology 14, 17588359221108687, 2022 | 1 | 2022 |
| Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma L Provenzano, V Cuccarini, M Platania, L Canziani, A Spagnoletti, ... Tumori Journal 107 (6), NP136-NP140, 2021 | 1 | 2021 |
| Metastatic sarcoma: tailored strategies for a heterogeneous disease M Grassi, A Spagnoletti, A Puccini memo-Magazine of European Medical Oncology 13, 179-184, 2020 | 1 | 2020 |
| Decoding KRAS mutation in non-small cell lung cancer patients receiving immunotherapy: A retrospective institutional comparison and literature review SB Urtecho, L Provenzano, A Spagnoletti, A Bottiglieri, C Pircher, ... Lung Cancer, 108051, 2024 | | 2024 |
| Characteristics and impact of real-world evidence studies in oncology: comprehensive mapping review of publications evaluating targeted therapies in solid tumours A Pellat, T Grinda, PC Morgado, A Prelaj, V Miskovic, A Valachis, I Zerdes, ... ESMO Real World Data and Digital Oncology 6, 100091, 2024 | | 2024 |
| Integrating radiomics and real-world data to predict immune-checkpoint inhibitors efficacy in advanced Non-Small Cell Lung Cancer L Provenzano, M Favali, L Mazzeo, A Spagnoletti, G Calareso, ... | | 2024 |
| 1320P Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy A Prelaj, M Sacco, V Miskovic, D Lorenzini, F Trovò, A Zec, LC Roisman, ... Annals of Oncology 35, S840-S841, 2024 | | 2024 |
| 178P Explainable radiomics, machine and deep learning models to predict immune-checkpoint inhibitor treatment efficacy in advanced non-small cell lung cancer patients L Provenzano, M Favali, L Mazzeo, A Spagnoletti, C Giani, G Calareso, ... Annals of Oncology 34, S252, 2023 | | 2023 |
